Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.
François B, Chastre J, Eggiman P, Laterre PF, Torres A, Sanchez M, Esser MT, Bishop B, Bonten M, Goosens H, Jafri HS. François B, et al. Among authors: laterre pf. Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S46-51. doi: 10.1093/cid/ciw245. Clin Infect Dis. 2016. PMID: 27481953 Review.
Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.
Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ, Mercier E, Garbino J, Luyt CE, Chastre J, Georgescu-Kyburz V, Rudolf MP, Gafner V, Lazar H, Koch H, Perez A, Krämer SD, Tamm M. Lu Q, et al. Among authors: laterre pf. J Antimicrob Chemother. 2011 May;66(5):1110-6. doi: 10.1093/jac/dkr046. Epub 2011 Mar 10. J Antimicrob Chemother. 2011. PMID: 21398296 Clinical Trial.
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, Larosa SP, Laterre PF, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. Bernard GR, et al. Among authors: laterre pf. Crit Care Med. 2014 Mar;42(3):504-11. doi: 10.1097/CCM.0000000000000043. Crit Care Med. 2014. PMID: 24335445 Clinical Trial.
Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial.
François B, Mercier E, Gonzalez C, Asehnoune K, Nseir S, Fiancette M, Desachy A, Plantefève G, Meziani F, de Lame PA, Laterre PF; MASTER 1 study group. François B, et al. Among authors: laterre pf. Intensive Care Med. 2018 Nov;44(11):1787-1796. doi: 10.1007/s00134-018-5229-2. Epub 2018 Oct 21. Intensive Care Med. 2018. PMID: 30343314 Clinical Trial.
Immunotherapies for COVID-19: lessons learned from sepsis.
Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, Jeannet R, Laterre PF, Hotchkiss RS, Moldawer LL. Remy KE, et al. Among authors: laterre pf. Lancet Respir Med. 2020 Oct;8(10):946-949. doi: 10.1016/S2213-2600(20)30217-4. Epub 2020 Apr 28. Lancet Respir Med. 2020. PMID: 32444269 Free PMC article. Review. No abstract available.
317 results